BeiGene Announces Approval of BRUKINSA (zanubrutinib) in the European Union for Treatment of Adults with Waldenström’s Macroglobulinemia
EU approval follows recent approvals for BRUKINSA including U.S., China, Brazil, and Canada The approval is based on Phase 3...






